Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 245.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: -8.99%
• EPS Growth: -18.16%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 320,802,500
• 10 Day Avg. Volume: 280,989
• 30 Day Avg. Volume: 245,143
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.93
• Price Target Upside: 34.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: AU$1.50 ▲(4.17% Upside)

Imricor Medical Systems' overall stock score is primarily impacted by its poor financial performance, characterized by negative margins and high leverage. While technical indicators show some positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves these areas unaddressed.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model

Company Description

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

How the Company Makes Money

Imricor Medical Systems, Inc. generates revenue through the sale of its MRI-compatible medical devices and systems to hospitals and healthcare facilities. The company leverages its proprietary technology to offer solutions that integrate with existing MRI systems, enhancing their utility for cardiac procedures. Revenue streams include the direct sale of devices, licensing agreements with medical institutions, and potential partnerships with MRI equipment manufacturers. The company's earnings are also influenced by the adoption of MRI-guided procedures in the medical community, driven by the growing demand for minimally invasive and precise cardiac treatments.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview

Summary

Imricor Medical Systems is facing significant financial challenges, with negative gross and net profit margins, high leverage, and negative equity posing solvency risks. Persistent cash burn and negative operating cash flow highlight cash management issues.

Income Statement

Imricor Medical Systems has shown consistent revenue growth, increasing from $639,704 in 2019 to $959,424 in 2024. However, the company has been struggling with negative gross and net profit margins. The gross profit margin has been negative each year, with the most recent year at -96.32%, and the net profit margin has consistently been deeply negative, reaching -3094.85% in 2024. This indicates significant challenges in profitability and cost management. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a worrisome trend with negative stockholders' equity of -$7,377,033 in 2024, indicating potential solvency risks. The debt-to-equity ratio is not meaningful due to negative equity, and while the total assets have increased over time, the leverage is high with total liabilities surpassing total assets. The equity ratio is also negative due to negative equity, highlighting financial instability.

Cash Flow

Imricor's cash flow situation is concerning, with a continuous negative operating cash flow and free cash flow, indicating cash burn. The free cash flow has been negative, reaching -$15,651,886 in 2024. Despite a positive financing cash flow from capital raises, the operating cash flow to net income ratio is negative, suggesting operating inefficiencies and challenges in generating cash from core operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	959.42K	615.57K	816.01K	696.27K	702.16K
Gross Profit	-924.12K	-1.12M	-1.53M	-1.90M	-397.67K
EBITDA	-15.55M	-21.87M	-16.47M	-18.93M	-11.62M
Net Income	-29.69M	-22.63M	-17.53M	-20.56M	-13.08M
Balance Sheet
Total Assets	21.62M	8.31M	13.70M	26.86M	33.57M
Cash, Cash Equivalents and Short-Term Investments	15.71M	831.52K	5.69M	18.52M	25.14M
Total Debt	21.35M	10.42M	4.49M	1.74M	1.39M
Total Liabilities	29.00M	17.06M	6.19M	4.46M	4.75M
Stockholders Equity	-7.38M	-12.83M	7.51M	22.40M	28.82M
Cash Flow
Free Cash Flow	-15.65M	-13.06M	-17.06M	-18.11M	-12.97M
Operating Cash Flow	-15.57M	-12.98M	-16.82M	-17.49M	-12.23M
Investing Cash Flow	-74.98K	-82.78K	-238.86K	-695.30K	-774.03K
Financing Cash Flow	30.33M	8.21M	3.94M	11.59M	33.02M

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.44
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Positive. The current price of 1.44 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.37, and above the 200-day MA of 1.43, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.35 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMR.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	66 Neutral	AU$40.76M	21.63	78.86%	2.40%	11.93%	2.39%
ARX	63 Neutral	AU$239.80M	-68.81	-4.10%	―	20.36%	64.81%
MDR	56 Neutral	AU$25.93M	-0.43	―	―	-48.41%	-6520.00%
IMR	48 Neutral	―	―	-432.03%	―	-8.99%	-18.16%
EMV	46 Neutral	AU$178.30M	-16.91	―	―	―	-257.32%
OSL	43 Neutral	AU$31.16M	-1.20	―	―	126.62%	33.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events

Imricor Medical Systems Expands Market Presence with New Securities Quotation

Imricor Medical Systems, Inc. has announced the application for the quotation of 11,250 securities on the ASX, reflecting the company’s ongoing efforts to enhance its market presence and financial flexibility. This move is expected to support Imricor’s strategic initiatives and operations, potentially strengthening its industry positioning and offering new opportunities for stakeholders.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Expands ASX Quotation with New Securities

Imricor Medical Systems, Inc. announced the application for the quotation of 344,900 new securities on the Australian Securities Exchange (ASX), with an issue date of September 6, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion, reflecting a significant step in its growth trajectory and offering potential implications for investors and stakeholders.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Advances U.S. Market Expansion with FDA Submission

Imricor Medical Systems, Inc. has submitted its Vision-MR Diagnostic Catheter for FDA 510(k) approval, marking a significant step towards expanding its MRI-compatible electrophysiology devices in the U.S. market. This move, along with the recent submission of the NorthStar 3D mapping system, aims to establish a comprehensive, radiation-free platform for cardiac procedures, potentially transforming the industry and enhancing Imricor’s market position.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Releases Shares from Voluntary Escrow, Boosting Market Liquidity

Imricor Medical Systems, Inc. announced the release of 242,875 Class A Common Stock from voluntary escrow, effective September 6, 2025. This move is part of the company’s ongoing efforts to manage its securities and may impact its market operations by increasing the liquidity of its shares. The release aligns with the company’s strategic objectives to expand its market presence and enhance shareholder value.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems’ 1H 2025 Investor Presentation Highlights Global Expansion Goals

Imricor Medical Systems, Inc. has released its 1H 2025 investor presentation, highlighting its ongoing commitment to expanding the reach of its iCMR technology in cardiac centers globally. The presentation underscores the company’s strategic focus on leveraging its innovative MRI-compatible solutions to enhance cardiac procedures, potentially impacting its market positioning and offering growth opportunities for stakeholders.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Advances in Cardiac Ablation Innovation

Imricor Medical Systems, Inc. has made significant strides in its operations and regulatory achievements, including the submission of a second Premarket Approval Module to the US FDA and receiving CE Mark approval for its second-generation products. The company is advancing its clinical trials, expanding its customer pipeline, and establishing new iCMR labs in Saudi Arabia. Despite a temporary revenue impact due to clinical trial participation, Imricor expects revenue growth as trials conclude and FDA approval is obtained. The company’s strong cash position supports its growth initiatives, positioning it as a transformative player in the rapidly growing electrophysiology market.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems to Announce FY25 1H Results

Imricor Medical Systems, Inc. has announced that it will release its financial results for the first half of fiscal year 2025 on August 26, 2025. The company will also host an investor webinar on the same day, featuring presentations from its Chair and CEO, Steve Wedan, and CFO, Jonathon Gut. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction, potentially impacting investor decisions and market perception.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Addresses Growing Cardiac Arrhythmia Challenge at Canaccord Conference

Imricor Medical Systems, Inc. highlighted the growing global challenge of cardiac arrhythmias, which are disturbances in heart rhythm that can lead to severe health events like strokes and sudden cardiac death. The company presented at the Canaccord Annual Growth Conference, emphasizing the increasing prevalence of arrhythmias in the U.S., which has doubled since 1990 and is projected to double again by 2030, affecting 4% of the population. This underscores the importance of Imricor’s mission to implement iCMR technology in cardiac centers worldwide, potentially improving patient outcomes and positioning the company as a leader in cardiac care innovation.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.